Huakang Biomedical Holdings Company Limited (HK:8622)
:8622
Want to see HK:8622 full AI Analyst Report?
Top Page
Huakang Biomedical Holdings Company Limited
(8622)
Select Model
Select Model
Rating:47Neutral
Price Target:
HK$0.33
▼(-22.62% Downside)
Action:Reiterated
Date:05/05/26
The score is primarily held back by persistent operating losses and negative operating/free cash flow, which outweigh the benefits of strong gross margins and low leverage. Technical signals are largely neutral and do not provide a strong offset, while valuation is constrained by a negative P/E and lack of dividend information.
Positive Factors
High gross margin
A ~63% gross margin indicates robust product-level economics and pricing power in the company's portfolio. Over the medium term this margin provides a structural buffer to absorb SG&A and R&D, enabling a clear pathway to operating leverage if fixed costs are controlled and revenue growth continues.
Negative Factors
Persistent operating losses
Chronic operating losses (operating margin ~-28%) indicate the business has not yet converted strong gross economics into profitable operations. Over months this continues to erode equity, reduces management flexibility, and makes achievement of sustainable profitability contingent on significant cost restructuring or faster revenue scaling.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margin
A ~63% gross margin indicates robust product-level economics and pricing power in the company's portfolio. Over the medium term this margin provides a structural buffer to absorb SG&A and R&D, enabling a clear pathway to operating leverage if fixed costs are controlled and revenue growth continues.
Read all positive factors
Huakang Biomedical Holdings Company Limited (8622) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$164.95M
Dividend YieldN/A
Average Volume (3M)2.14M
Price to Earnings (P/E)―
Beta (1Y)0.35
Revenue Growth11.68%
EPS Growth-16.13%
CountryHK
Employees91
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.00
Shares Outstanding515,472,000
10 Day Avg. Volume1,472,000
30 Day Avg. Volume2,141,866
Financial Highlights & Ratios
PEG Ratio-2.40
Price to Book (P/B)3.83
Price to Sales (P/S)6.93
P/FCF Ratio-59.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Huakang Biomedical Holdings Company Limited Business Overview & Revenue Model
Company Description
Huakang Biomedical Holdings Company Limited, an investment holding company, engages in the research, development, manufacture, marketing, and sale of in-vitro diagnostic (IVD) reagents in the People's Republic of China. It offers male and female f...
How the Company Makes Money
null...
Huakang Biomedical Holdings Company Limited Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
72
Positive
Cash Flow
25
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 25.77M | 28.28M | 25.36M | 24.63M | 25.33M | 26.13M |
| Gross Profit | 17.50M | 17.77M | 17.07M | 16.09M | 16.91M | 16.46M |
| EBITDA | -3.62M | -6.17M | -3.41M | -2.55M | 188.00K | -852.00K |
| Net Income | -4.75M | -5.01M | -4.16M | -5.78M | -3.08M | -4.22M |
Balance Sheet | ||||||
| Total Assets | 66.75M | 66.64M | 65.22M | 65.31M | 66.40M | 67.06M |
| Cash, Cash Equivalents and Short-Term Investments | 36.73M | 41.96M | 36.49M | 32.94M | 33.30M | 36.21M |
| Total Debt | 6.42M | 4.96M | 4.08M | 5.14M | 1.88M | 1.78M |
| Total Liabilities | 14.69M | 15.46M | 11.17M | 14.30M | 9.88M | 9.36M |
| Stockholders Equity | 52.03M | 51.15M | 54.05M | 51.02M | 56.52M | 57.70M |
Cash Flow | ||||||
| Free Cash Flow | -3.71M | -3.29M | -5.05M | -1.55M | 475.00K | -4.71M |
| Operating Cash Flow | -1.72M | -2.21M | -3.06M | -48.00K | 1.29M | -2.38M |
| Investing Cash Flow | 482.00K | 2.32M | -4.42M | -1.15M | -6.11M | -2.06M |
| Financing Cash Flow | 1.27M | 4.78M | 6.30M | 1.02M | 2.32M | -1.37M |
Huakang Biomedical Holdings Company Limited Technical Analysis
Negative
0.42
Price Trends
0.33
Negative
0.36
Negative
0.39
Negative
Market Momentum
>-0.01
Positive
46.25
Neutral
44.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8622, the sentiment is Negative. The current price of 0.42 is above the 20-day moving average (MA) of 0.33, above the 50-day MA of 0.33, and above the 200-day MA of 0.39, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 46.25 is Neutral, neither overbought nor oversold. The STOCH value of 44.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:8622.
Huakang Biomedical Holdings Company Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | HK$203.00M | -0.15 | -30.35% | ― | -11.89% | -290.48% | |
52 Neutral | HK$764.63M | 11.90 | -3.39% | ― | -15.98% | 93.93% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | HK$164.95M | -19.08 | -11.77% | ― | 11.68% | -16.13% | |
45 Neutral | HK$167.36M | -0.28 | -69.10% | ― | 1.92% | -468.15% | |
45 Neutral | HK$155.13M | -3.07 | -30.35% | ― | -12.03% | 6.24% | |
42 Neutral | HK$588.38M | -13.53 | 9.48% | ― | -36.32% | 78.17% |
* Healthcare Sector Average
HK:8622
Huakang Biomedical Holdings Company Limited
0.33
-0.08
-18.75%
HK:0858
Extrawell Pharmaceutical Holdings Limited
0.07
0.02
40.00%
HK:1011
China NT Pharma Group Co., Ltd.
0.61
0.19
45.24%
HK:1312
Kontafarma China Holdings Ltd
0.03
<0.01
3.45%
HK:1498
PuraPharm Corp. Ltd.
0.30
-0.24
-44.44%
HK:1652
Fusen Pharmaceutical Co., Ltd.
1.10
0.81
279.31%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.